South Korean CRO MediCROstar Joins Medidata Solutions' Channel Partner Program

South Korean CRO MediCROstar Joins Medidata Solutions' Channel Partner Program

Companies Kick Off Partnership with Co-hosted EDC Seminar in Seoul on September 10th

 

NEW YORK, N.Y. - September 9, 2010 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that South Korean contract research organization (CRO) MediCROstar has joined Medidata's channel partner program for CROs and other service providers. In addition to bringing the proven capabilities of the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution, the partnership will enable MediCROstar to further expand its presence in the APAC region and continue to build its stake in the global clinical trials marketplace.

 

Founded in 2006, Seoul-based MediCROstar specializes in electronic case report format (eCRF) data management and protocol development for investigator-initiated trials. With strong expertise and experience managing clinical trials across South Korea and India, MediCROstar executives helped the Korea Food and Drug Administration (KFDA) write formal guidance on conducting EDC trials. As a result, the company has quickly become one of South Korea's key players in clinical development as the growth in clinical trials in the region has driven increasing need for technologies as well as outsourcing organizations to help efficiently manage the studies. MediCROstar looks to the Medidata partner program as a key driver of its global expansion and is developing new services around Medidata Rave to offer customers the efficient data management, local language capabilities and ease of use of the proven Rave platform.

 

"The adoption of EDC technology is a growing trend in South Korea, mirroring its use in the global pharmaceutical industry, and we have looked to Medidata's partner program to help us field the increasing demand for innovative clinical technologies," said Inyoung Choi, director, MediCROstar. "We look forward to providing customers with an industry-leading EDC solution, Medidata Rave, as we build a partnership with an experienced and well-established global vendor that will play a key role in supporting our expansion into the international clinical trials community."

 

MediCROstar expects to leverage the Medidata Rave solution for a number of Phase III global multinational trials over the next year.

 

"We are very happy to welcome MediCROstar as a Medidata channel partner and to collaborate with them to meet customer demand for Medidata Rave in South Korea, India and other Asian markets where sponsors can reach a range of diverse patient populations," said Graham Bunn, vice president, partnerships. "MediCROstar brings invaluable in-depth knowledge of the clinical development landscape in the emerging South Korean and the broader Asian market and our customers will benefit from their regional expertise."

 

On September 10th, Medidata and MediCROstar will co-host a seminar titled "Safe Transfer-From Paper CRF to eCRF" at EL Tower, 24 Yangjae-dong, Seocho-gu, Seoul, South Korea. The seminar will outline the sponsor and CRO benefits of the Medidata Rave solution and introduce trends of data management in Korea. Presenters include Dong-Seok Yim, MediCROstar CEO, and Takeru Yamamoto, head of APAC at Medidata Solutions. For more information, please visit: www.medicrostar.com.

 

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, the program has grown to include more than 25 partners (including nine organizations headquartered in Asia), ranging from smaller clinical consultancies to large, global CROs. For more information, please visit: www.mdsol.com/partnerships/cros.htm.


About MediCROstar
MediCROstar Co., LTD. (www.medicrostar.com) is a CRO spun off from the Catholic Medical Center in Korea in 2006. Since its foundation, MediCROstar's services have drawn attention in the Korean market for its excellence in data management using e-CRF system and protocol development for investigator initiated trials. In Korea, the CRO services as a category of business were initiated in early 2000s. In spite of the short history, the need for CRO services is briskly increasing driven by the remarkable growth of global clinical trials. MediCROstar aims to specialize its services based upon the academic excellence and state-of-the art skills.

About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading global provider of SaaS-based clinical development solutions that enhance the efficiency of customers' clinical trials. For over 10 years, Medidata has consistently brought next-generation innovation to the life science industry to lower the total cost of clinical development through informed trial planning and management, optimized clinical processes and platform interoperability. Medidata's advanced solutions address key functions throughout the clinical development process including protocol development (Medidata Designer®), trial planning and management (Medidata Grants Manager®, Medidata CRO Contractor®), user and learning management (iMedidataTM), randomization and trial supply management (Medidata BalanceTM), monitoring (Medidata Rave Monitor, Medidata Rave Targeted SDV), Serious Adverse Events capture (Medidata Rave Safety Gateway) and clinical data capture, management and reporting (Medidata Rave®). Our diverse customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Contact:
Susan McCarron
Lois Paul & Partners
781.782.5767
[email protected]

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.